Results 191 to 200 of about 55,173 (262)

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble   +7 more
wiley   +1 more source

Severity of Cardiovascular Autonomic Neuropathy Is Linked to Increasing Levels of Circulating Proinflammatory Cytokines

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular autonomic neuropathy (CAN) is a severe form of diabetic neuropathy affecting approximately one in five people with diabetes and is a major predictor of cardiovascular mortality. Low‐grade inflammation may contribute to CAN development, but the exact inflammatory factors associated with CAN remain unclear.
Michelle Damgaard   +9 more
wiley   +1 more source

Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Tirzepatide has demonstrated substantial weight‐loss efficacy in clinical trials, but real‐world evidence from routine digital prescribing remains limited. Methods We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order‐
Onayomi Rosenior‐Patten   +7 more
wiley   +1 more source

Relationship Between hsCRP, Glycaemic Control and Response to Sotagliflozin in Type 1 Diabetes: A Post Hoc Analysis of the inTandem3 Trial

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Luxcia Kugathasan   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy